Is Freenome profitable in 2026?

No. As of its July 21, 2026 Nasdaq debut as FRNM, Freenome remains pre-revenue and clinical-stage, with its CLIA-certified lab only processing commercial samples ahead of full FDA approval, after raising roughly $1.35B to $1.4B in private financing since 2014.

Has Freenome's blood test for colorectal cancer been approved by the FDA?

Not yet as of July 21, 2026. Freenome submitted its PMA application in August 2025 for SimpleScreen CRC, with an FDA decision expected mid-2026. Rival Guardant Health's Shield test already received FDA approval on July 26, 2024.

Who is Freenome's biggest competitor?

Guardant Health is Freenome's closest direct rival; its Shield blood-based colorectal cancer test won FDA approval July 26, 2024, roughly two years ahead of Freenome's pending SimpleScreen CRC approval, giving Guardant first-mover market share as of July 2026.

Could AI replace Freenome's core product?

Unlikely. Freenome's moat is proprietary clinical trial data (PREEMPT CRC cohort), pending FDA PMA approval, exclusive commercial deals, and CLIA lab infrastructure, none of which a general AI model can replicate; AI is used internally to improve its own detection algorithms, per its July 9, 2026 readout.

Who owns Freenome now that it's public?

Freenome became publicly traded on Nasdaq under ticker FRNM on July 21, 2026 via a business combination with SPAC Perceptive Capital Solutions Corp; no single parent owns it, though Roche, a16z, Bain Capital, and other VCs remain major shareholders.

Is Freenome's US commercial partner Abbott or Exact Sciences?

Sources conflict as of July 2026. An August 2025 deal named Exact Sciences as the US commercialization partner worth up to $885M, while Freenome's July 9, 2026 press release instead names Abbott as the exclusive US commercial partner for SimpleScreen CRC.

AI companies and labs · United States

Freenome

freenome.com ↗

Blood test maker chasing FDA approval for colorectal cancer screening, pre-revenue after 12 years.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from mid-2026 · Every call on the record Checkpoint: FDA PMA decision on first-generation SimpleScreen CRC

The call

Freenome built the science and the paperwork trail, but the whole twelve-year, $1.35 billion bet rides on one FDA yes or no landing this year while Guardant already sells its rival test.

Freenome is a medical testing company trying to detect colon cancer early using a blood sample instead of requiring a colonoscopy. The company has spent 12 years and over 1 billion dollars building its test and getting closer to FDA approval, but Guardant Health already got their blood test approved two years ago and is selling it now. Freenome's entire future depends on whether the FDA approves their test in the coming months, if they get approval, they can finally compete; if they do not, the company runs out of runway with no revenue to show for over a decade of work.

Why

AI pressure: None apparent. AI models can't copy Freenome's trial data, FDA filing, or lab setup. AI here is a tool inside their pipeline, not a hunter outside it. Could AI do the core job? Unlikely.

Bigger players: Guardant Health (Shield test). Guardant's Shield already has FDA approval since July 2024 and two years of paying customers while Freenome still waits for a decision. Could a giant copy it? Probably.

What protects it. A large completed trial, ACS guideline inclusion, and signed deals with Roche and Abbott that a new entrant cannot quickly copy.

What would change this call

FDA issues a PMA decision on SimpleScreen CRC, expected mid-2026. Approval activates the regulatory moat and commercial launch; rejection or delay extends the pre-revenue gap versus Guardant.
SEC filings or press releases confirm whether Abbott or Exact Sciences is the exclusive US commercial partner. Resolves conflicting 2025 and 2026 statements about who actually distributes SimpleScreen CRC in the US.
Post-approval quarterly revenue or test-volume figures compared to Guardant Shield's uptake. Shows whether Freenome is capturing share from Guardant or merely splitting a growing category with a two-year incumbent.

Key numbers

Raised $1.35B to $1.4B total, still pre-revenue (Dec 2025)
85% CRC sensitivity, 90% specificity in pivotal study (Jan 2026)
Headcount fell from 681 to about 501 staff (Dec 2025)

Named risks

FDA PMA decision on SimpleScreen CRC still pending as of Jul 21 2026, entire commercialization plan hinges on this binary event. Severity: high
Guardant Health already holds a two-year head start with an FDA-approved competing blood-based CRC test. Severity: high
Conflicting public statements over whether Abbott or Exact Sciences is the true exclusive US commercial partner. Severity: medium
Headcount fell from 681 in 2023 to 501 by Dec 2025 amid restructuring, signaling ongoing cost pressure pre-revenue. Severity: medium
Category sentiment risk from GRAIL's trial miss and securities litigation could spill over to blood-based screening investors broadly. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Guardant Health	losing to	Shield test FDA-approved Jul 26 2024, two years ahead of Freenome's pending SimpleScreen CRC decision as of Jul 2026
Exact Sciences	contesting	Stool-based Cologuard incumbent but also signed Aug 2025 US commercialization deal for Freenome's CRC test, worth up to $885M
GRAIL	gaining on	GRAIL missed NHS-Galleri primary endpoint Feb 2026 and faces securities class action filed Jul 15 2026, denting MCED category sentiment
Abbott	contesting	Named as exclusive US commercial partner for SimpleScreen CRC in Jul 9 2026 press release, contradicting earlier Exact Sciences deal

Questions people ask

Is Freenome profitable in 2026?: No. As of its July 21, 2026 Nasdaq debut as FRNM, Freenome remains pre-revenue and clinical-stage, with its CLIA-certified lab only processing commercial samples ahead of full FDA approval, after raising roughly $1.35B to $1.4B in private financing since 2014.
Has Freenome's blood test for colorectal cancer been approved by the FDA?: Not yet as of July 21, 2026. Freenome submitted its PMA application in August 2025 for SimpleScreen CRC, with an FDA decision expected mid-2026. Rival Guardant Health's Shield test already received FDA approval on July 26, 2024.
Who is Freenome's biggest competitor?: Guardant Health is Freenome's closest direct rival; its Shield blood-based colorectal cancer test won FDA approval July 26, 2024, roughly two years ahead of Freenome's pending SimpleScreen CRC approval, giving Guardant first-mover market share as of July 2026.
Could AI replace Freenome's core product?: Unlikely. Freenome's moat is proprietary clinical trial data (PREEMPT CRC cohort), pending FDA PMA approval, exclusive commercial deals, and CLIA lab infrastructure, none of which a general AI model can replicate; AI is used internally to improve its own detection algorithms, per its July 9, 2026 readout.
Who owns Freenome now that it's public?: Freenome became publicly traded on Nasdaq under ticker FRNM on July 21, 2026 via a business combination with SPAC Perceptive Capital Solutions Corp; no single parent owns it, though Roche, a16z, Bain Capital, and other VCs remain major shareholders.
Is Freenome's US commercial partner Abbott or Exact Sciences?: Sources conflict as of July 2026. An August 2025 deal named Exact Sciences as the US commercialization partner worth up to $885M, while Freenome's July 9, 2026 press release instead names Abbott as the exclusive US commercial partner for SimpleScreen CRC.

Timeline

2026-07-21Freenome begins trading on Nasdaq as FRNM after SPAC merger closes
2026-07-09Updated SimpleScreen CRC meets all primary and secondary endpoints in pivotal study
2026-05-27SimpleScreen CRC included in updated American Cancer Society CRC screening guideline
2026-01-07SimpleScreen CRC shows 85% CRC sensitivity, 22% for advanced precancerous lesions at 90% specificity
2025-12-05Freenome announces SPAC merger with Perceptive Capital Solutions Corp
2025-11-21Roche signs ex-US licensing deal worth $200M+ plus $75M option-fee investment
2025-08Exact Sciences signs US commercialization deal worth up to $885M for CRC blood test
2025-08Freenome submits FDA Premarket Approval application for SimpleScreen CRC
2024-07-26Competitor Guardant Health's Shield test receives FDA approval
2024-02-15Freenome raises $254M round led by Roche

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere